279 related articles for article (PubMed ID: 19202079)
1. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Chen H; Liakou CI; Kamat A; Pettaway C; Ward JF; Tang DN; Sun J; Jungbluth AA; Troncoso P; Logothetis C; Sharma P
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2729-34. PubMed ID: 19202079
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Liakou CI; Kamat A; Tang DN; Chen H; Sun J; Troncoso P; Logothetis C; Sharma P
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14987-92. PubMed ID: 18818309
[TBL] [Abstract][Full Text] [Related]
3. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Carthon BC; Wolchok JD; Yuan J; Kamat A; Ng Tang DS; Sun J; Ku G; Troncoso P; Logothetis CJ; Allison JP; Sharma P
Clin Cancer Res; 2010 May; 16(10):2861-71. PubMed ID: 20460488
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
5. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.
Sun J; Schiffman J; Raghunath A; Ng Tang D; Chen H; Sharma P
Cancer Immun; 2008 May; 8():9. PubMed ID: 18503261
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease.
Argüello RJ; Albareda MC; Alvarez MG; Bertocchi G; Armenti AH; Vigliano C; Meckert PC; Tarleton RL; Laucella SA
PLoS One; 2012; 7(5):e35966. PubMed ID: 22574131
[TBL] [Abstract][Full Text] [Related]
8. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
9. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Fan X; Quezada SA; Sepulveda MA; Sharma P; Allison JP
J Exp Med; 2014 Apr; 211(4):715-25. PubMed ID: 24687957
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
11. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
[TBL] [Abstract][Full Text] [Related]
12. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.
Tiriveedhi V; Fleming TP; Goedegebuure PS; Naughton M; Ma C; Lockhart C; Gao F; Gillanders WE; Mohanakumar T
Breast Cancer Res Treat; 2013 Feb; 138(1):109-18. PubMed ID: 22678162
[TBL] [Abstract][Full Text] [Related]
13. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
14. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
15. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
17. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
18. Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production.
Watari K; Konnai S; Maekawa N; Okagawa T; Suzuki Y; Murata S; Ohashi K
BMC Vet Res; 2019 Oct; 15(1):380. PubMed ID: 31665022
[TBL] [Abstract][Full Text] [Related]
19. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
Thompson RH; Allison JP; Kwon ED
Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
[TBL] [Abstract][Full Text] [Related]
20. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner.
Zheng J; Chan PL; Liu Y; Qin G; Xiang Z; Lam KT; Lewis DB; Lau YL; Tu W
PLoS One; 2013; 8(12):e82203. PubMed ID: 24312642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]